Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increases costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company’s latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
(Date:11/18/2014)... November 18, 2014 Alanda Software, ... Transparency Reporting solutions, announced today that a top ... its Consummate Provider™ solution in both the U.S. ... Global, SaaS based, Data Quality remediation portal, designed ... third party Providers improve their ability to capture, ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Meeting Report the Use of Haptoglobin Typing,to Predict ... in,Diabetics, MONTVALE, N.J., Nov. 10 Synvista,Therapeutics, ... the Annual Scientific,Sessions of the American Heart Association, ... to determine haptoglobin (Hp) genotype utilizing,intellectual property licensed ...
... TOKYO, November 10 HOYA Corporation today,announced financial results ... were 128.3 billion yen for the quarter, representing an,increase ... quarter of 2007,mainly reflecting the additional results of PENTAX ... year., Operating income was 20.6 billion yen, a ...
... Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology,International, Inc. (OTC ... developer, producer and distributor of nutrients for plants ... today announced that,the Company will present at the ... on November 19-21, 2008 at the Wynn Hotel ...
Cached Biology Technology:Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 2Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 3Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 4Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 5Hoya Announces Second Quarter and First Half Financial Results for FY2008 2Yongye Biotechnology to Present at Roth Capital 'China Comes to Vegas' Conference 2Yongye Biotechnology to Present at Roth Capital 'China Comes to Vegas' Conference 3
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
(Date:11/7/2014)... 7, 2014  In conjunction with the Glendale ... The Community Foundation of the Verdugos has announced the " ... PROJECT," a $250,000 initiative to keep the Verdugo Regional Crime ... first six months of existence, the Lab has processed more ... local law enforcement. "Because our number one priority ...
(Date:11/6/2014)... a predator. Except when that predator runs so fast that ... its size, is the fastest creature on Earth. Some of ... (at about five miles per hour). The fastest human can ... from the tiger beetle, a person would have to hit ... a problem. At peak speeds, everything becomes a blur. They ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2The tiger beetle: Too fast to see 2
... Most creatures face compromises when they reproduce the more ... they can invest in each one. But do the same ... plants with bigger, showier flowers can make fewer of them ... say. A new study by researchers at the National Evolutionary ...
... will partner with the Entomological Society of Brazil to ... new book series Entomology in Focus. Prof. Fernando L.Consli ... both the journal and the book series. ... bimonthly journal publishing original articles written by Brazilian and ...
... identified key steps in how certain molecules alter a cell,s ... of their research, published in the December 13 issue of ... triggers the metastatic spread of cancer cells and wound-healing. ... Inoue, Ph.D., an assistant professor of cell biology and member ...
Cached Biology News:Bouquet bargains 2Springer to publish journal and book series for Entomological Society of Brazil 2Rearranging the cell's skeleton 2
... HistoMark Biotin Streptavidin-HRP Systems provide ... and intracellular antigens in frozen or ... These systems also facilitate double ... can be performed simultaneously with primary ...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... three step procedure (PCR, Exonuclease III digestion ... one day. The typical cloning efficiency using ... Features and Benefits: , , Universal - ... expression vector , High Cloning Efficiency - ...
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
Biology Products: